ESR1 and breast cancer: Furthermore, knockdown of DSCAM-AS1 in these tamoxifen-resistant cells reduced the proliferation rate to the level of parental MCF7 cells, suggesting a role of DSCAM-AS1 in tumor progression and tamoxifen resistance in ER+ breast cancer [70, 71].